4D MOLECULAR THERAPEUTICS, INC. 4D Molecular Therapeutics, Inc. Share Price
Equities
FDMT
US35104E1001
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.25 USD | -1.19% |
|
-7.92% | +14.76% |
| Sales 2024 * | 6.35M 529M | Sales 2025 * | 7.38M 615M | Capitalization | 1.19B 99.17B |
|---|---|---|---|---|---|
| Net income 2024 * | -151M -12.59B | Net income 2025 * | -164M -13.67B | EV / Sales 2024 * | 112 x |
| Net cash position 2024 * | 480M 40.06B | Net cash position 2025 * | 319M 26.56B | EV / Sales 2025 * | 118 x |
| P/E ratio 2024 * |
-7.46
x | P/E ratio 2025 * |
-7.85
x | Employees | 147 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.46% |
More Fundamentals
* Assessed data
More news
Latest transcript on 4D Molecular Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.19% | ||
| 1 week | -7.92% | ||
| Current month | -27.02% | ||
| 1 month | -31.72% | ||
| 3 months | +32.86% | ||
| 6 months | +119.34% | ||
| Current year | +14.76% |
1 week
22.75
26.92
1 month
22.7534.20
Current year
16.6436.25
1 year
9.4436.25
3 years
5.3239.37
5 years
5.3255.11
10 years
5.3255.11
| Managers | Title | Age | Since |
|---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 12/13/12 |
David Kirn
FOU | Founder | 62 | 12/13/12 |
Uneek Mehra
DFI | Director of Finance/CFO | - | 12/23/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Milligan
CHM | Chairman | 63 | 01/20/01 |
Susannah Gray
BRD | Director/Board Member | 63 | 01/20/01 |
Charles Theuer
BRD | Director/Board Member | 60 | 01/16/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 16 M€ | -8.49% | ||
| 0.06% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 23.25 | -1.19% | 322,784 |
| 25/24/25 | 23.53 | -2.97% | 453,265 |
| 24/24/24 | 24.25 | -2.26% | 290,425 |
| 23/24/23 | 24.81 | -5.99% | 565,556 |
| 22/24/22 | 26.39 | +4.51% | 484,648 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.25
USD
Average target price
54.22
USD
Spread / Average Target
+133.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.76% | 1.19B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- FDMT Stock
